Patents and other intellectual property rights are crucial to TheraMAB's business
One of the key aspects of the Company’s policy is to file patent applications to protect its technology, product candidates, development of these product candidates and their potential usage for treatment of a number of diseases. Protection of the results of improvements of drug candidates is also important to the development of the Company’s business. The Company provides protection for all aspects of its activity by filing follow-up patents of existing filed patent applications as well as by filing patents to potentially limit the freedom-to-operate of the Company’s competitors. In general, the Company aims to protect world-wide any inventions that hold future value for in-house development or for out-licensing.
The Company has filed a number of patent applications and has obtained several patents related to application of current drug-candidate TAB08 for the treatment of diseases such as Rheumatoid Arthritis and B-cell Chronic Lymphocytic Leukemia as well as applications of TAB08 ex-vivo.